​

Carisma Therapeutics (CARM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CARM Stock Forecast

Carisma Therapeutics (CARM) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 1263.64% increase from the last price of $0.44.

- $1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $0.44

CARM Stock Rating

Carisma Therapeutics stock's rating consensus is Hold, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (33.33%), 4 Hold (66.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 6 0 4 2 Strong Sell Sell Hold Buy Strong Buy

CARM Price Target Upside V Benchmarks

TypeNameUpside
StockCarisma Therapeutics1263.64%
SectorHealthcare Stocks 27.56%
IndustryBiotech Stocks 68.41%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.44$0.44$0.44
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-11--2
May, 25-12--3
Apr, 25-13--4
Mar, 25-13--4
Feb, 25-13--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 11, 2024Justin ZelinBTIG$6.00$1.91214.14%1263.64%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024EF HuttonBuyinitialise
Jun 26, 2024BTIGUnderperformUnderperformhold
May 10, 2024H.C. WainwrightBuyBuyhold
Apr 02, 2024H.C. WainwrightBuyBuyhold
Nov 30, 2022Zacks Investment ResearchBuyupgrade

Financial Forecast

EPS Forecast

$-600 $-480 $-360 $-240 $-120 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.79$-4.47$-575.42$-2.59$-1.46----
Avg Forecast$-3.87$-1.40$-3.80$-2.52$-1.20$-0.62$-0.62$-0.38$-0.38
High Forecast$-3.25$-1.18$-3.19$-2.43$-0.99$-0.49$-0.41$-0.31$-0.31
Low Forecast$-4.69$-1.70$-4.37$-2.62$-1.37$-0.75$-0.83$-0.43$-0.43
Surprise %23.77%219.29%15042.63%2.78%21.67%----

Revenue Forecast

$5M $13M $21M $29M $37M $45M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.24M$26.54M$9.83M$14.92M-----
Avg Forecast$11.22M$6.51M$40.00M$13.53M$21.41M$20.32M$10.00M$33.26M$9.98M
High Forecast$13.06M$7.58M$44.59M$15.65M$23.79M$22.58M$11.11M$36.96M$11.10M
Low Forecast$9.85M$5.72M$35.10M$11.40M$18.49M$17.55M$8.64M$28.72M$8.62M
Surprise %0.11%307.45%-75.42%10.27%-----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-28.32M$-40.77M$-61.23M$-86.88M$-60.48M----
Avg Forecast$-129.63M$-46.93M$-127.39M$-86.88M$-39.57M$-20.79M$-20.79M$-12.53M$-12.74M
High Forecast$-108.99M$-39.46M$-107.09M$-81.36M$-33.09M$-16.43M$-13.74M$-10.48M$-10.48M
Low Forecast$-157.16M$-56.90M$-146.38M$-87.77M$-46.05M$-25.14M$-27.83M$-14.58M$-14.58M
Surprise %-78.15%-13.12%-51.94%-52.83%----

CARM Forecast FAQ

Is Carisma Therapeutics stock a buy?

Carisma Therapeutics stock has a consensus rating of Hold, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Carisma Therapeutics is a neutral investment for most analysts.

What is Carisma Therapeutics's price target?

Carisma Therapeutics's price target, set by 6 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 1263.64% change from the previous closing price of $0.44.

How does Carisma Therapeutics stock forecast compare to its benchmarks?

Carisma Therapeutics's stock forecast shows a 1263.64% upside, outperforming the average forecast for the healthcare stocks sector (27.56%) and outperforming the biotech stocks industry (68.41%).

What is the breakdown of analyst ratings for Carisma Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.

What is Carisma Therapeutics’s EPS forecast?

Carisma Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.62, marking a -57.53% decrease from the reported $-1.46 in 2024. Estimates for the following years are $-0.62 in 2026, $-0.38 in 2027, and $-0.38 in 2028.

What is Carisma Therapeutics’s revenue forecast?

Carisma Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $20.32M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10M, followed by $33.26M for 2027, and $9.98M for 2028.

What is Carisma Therapeutics’s net income forecast?

Carisma Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-20.787M, representing a -65.63% decrease from the reported $-60.477M in 2024. Projections indicate $-20.785M in 2026, $-12.531M in 2027, and $-12.739M in 2028.